Sorafenib

Sorafenib is an oral multikinase inhibitor with both antiproliferative and antiangiogenic properties used as an active pharmaceutical ingredient. Mediocon Inc supplies high-purity Sorafenib API conforming to BP / EP / USP specifications from our GMP-certified facility in Aurangabad, Maharashtra, India.

Sorafenib inhibits multiple kinases including RAF kinases, VEGFR, and PDGFR, blocking tumor cell proliferation and angiogenesis. It is indicated for unresectable hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma.

Key Features

• High-purity pharmaceutical grade API
• BP / EP / USP / FCC / NF compliant
• Full CoA and MSDS documentation
• GMP certified manufacturing

Applications

• Hepatocellular carcinoma (HCC) treatment
• Renal cell carcinoma (RCC)
• Differentiated thyroid carcinoma
• Targeted oncology therapy formulations

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings